3Sixty Pharma Solutions

3Sixty Pharma Solutions

Pre-clinical
San Diego, United StatesFounded 20103sixtypharma.com

3Sixty Pharma Solutions is a well-established, US-based service firm that acts as a strategic partner to pharmaceutical, biotechnology, and medical device companies. It differentiates itself through a flexible, 'fractional team' model, leveraging a deep network of seasoned experts averaging 25+ years of industry experience to provide just-in-time support. The company has a proven track record, having completed over 1,500 projects across more than 15 therapeutic areas, focusing on expanding client capacity, streamlining operations, and navigating complex development and regulatory challenges.

Market Cap
Private
Pipeline
Patents
Publications

Private Company

Funding information not available

AI Company Overview

3Sixty Pharma Solutions is a well-established, US-based service firm that acts as a strategic partner to pharmaceutical, biotechnology, and medical device companies. It differentiates itself through a flexible, 'fractional team' model, leveraging a deep network of seasoned experts averaging 25+ years of industry experience to provide just-in-time support. The company has a proven track record, having completed over 1,500 projects across more than 15 therapeutic areas, focusing on expanding client capacity, streamlining operations, and navigating complex development and regulatory challenges.

NeuroscienceOncology and HematologyCell and Gene TherapyCardiovascular, Endocrine, MetabolicGastroenterologyImmunology & InflammationInfectious Diseases & VaccinesDermatologyOphthalmologyPediatricsRare DiseaseRespiratoryWomen's HealthBiosimilars

Technology Platform

3Sixty's core platform is its extensive, vetted network of over 20,000 life sciences subject-matter experts and its operational model for providing flexible, just-in-time, fractional team support to client companies.

Opportunities

Growth is driven by the increasing complexity of drug development (e.g., cell/gene therapy), the rise of virtual biotechs needing flexible expertise, and persistent industry pressure to control R&D costs and accelerate timelines.
The company's on-demand model is ideally suited to these trends.

Risk Factors

Key risks include dependence on the quality and retention of its expert network, susceptibility to cyclical swings in biotech R&D spending, intense competition from large CROs and boutique firms, and the scalability challenges of a high-touch service model.

Competitive Landscape

Competes with large full-service CROs (e.g., IQVIA), management consultants, and boutique firms. Differentiation lies in its agile, expert-network model, offering deep hands-on experience and flexible teaming without the overhead of large infrastructure or high-level strategy-only consulting.